Following the release of encouraging clinical trial data, shares of NanoViricides, Inc. (NYSE: NNVC) are demonstrating a bullish trend on US stock charts. As of the latest current-market check, NNVC stock increased by 7.92% to $3.27.
Table of Contents
Toggle- Breakthrough Findings On NV-387
- Efficacy Across Multiple Models
- Potential Revolutionary Antiviral Agent
Breakthrough Findings On NV-387
NanoViricides (NNVC) reported that its leading clinical-stage broad-spectrum antiviral drug candidate, NV-387, exhibits an ideal flat blood concentration profile for an extended duration upon oral administration in two different animal models. This rare but highly desirable extended flat time profile of NV-387 in the bloodstream enables a sustained antiviral effect over a prolonged period, allowing for infrequent dosing regimens.
Specifically, the blood concentration of NV-387 peaked within the first hour and remained nearly constant for eight hours or longer. Subsequently, the concentration declined to baseline at around twelve hours following the oral administration of the initial dose. This was consistently observed in studies involving rats and dogs.
Efficacy Across Multiple Models
Additionally, NanoViricides recently reported that when NV-387 was administered as a slow bolus intravenous infusion, it resulted in a relatively flat blood concentration plateau with a very slow decline over a 24-hour period in a cynomolgus monkey model. The company had previously demonstrated that orally administered NV-387 produced strong antiviral effects against several respiratory viruses.
In lethal infections with hCoV-NL63, RSV, and Influenza A/H3N2, orally administered NV-387 outperformed approved therapeutics where available. Notably, in a rat model of deadly lung infection with RSV A2, NV-387 allowed for the full recovery from RSV infection.
Potential Revolutionary Antiviral Agent
First-in-class, broad-spectrum antiviral medication NV-387, may revolutionize treatment for viruses including RSV, COVID-19, influenza, and maybe others. NNVC's claim is also supported by non-clinical pharmacokinetic studies of the medication when administered orally that NV-387's systemic circulation and direct antiviral actions are responsible for the strong antiviral effects shown in animal efficacy trials.
NanoViricides also highlighted that NV-387 may be among the first or one of the few nanomedicines effective upon oral administration, a notable advancement given that nanomedicines are typically restricted to injectable or topical delivery methods.